Molecular

Utilizing 18F-FET PET when conventional MRI falls short offers valuable information about the effectiveness of state-of-the-art treatments.

Flornaptitril is on track to become the first and only federally approved agent of its kind to simultaneously detect tau and beta-amyloid plaque.

Nearly 30% of patients showed lymph node uptake on PET/CT scans more than six weeks after their second dose of the Pfizer-BioNTech vaccine.

University of Virginia School of Medicine researchers reported positive results after using their imaging technique in a small pilot study.

Case Western Reserve University developed the gadolinium material, which is expected to be tested in 30 healthy participants beginning late next month.

The Nobody Left Behind or NOBLE Registry aims to establish prostate-specific membrane antigen SPECT imaging as a cost-effective and widely available alternative to PSMA-PET.

With the help of Phoenix's advanced industrial imaging capabilities, the new entity hopes to ramp up its production of molybdenum-99.

Hoag Family Cancer Institute in California is testing a radiotracer for myeloma and PSMA therapy in patients with high-risk prostate cancer.

Patients visiting Quincy Medical Group will no longer have to undergo such exams on a mobile truck unit.

The PET radiotracer targets inflammation and quickly clears from the bloodstream, nuclear medicine experts reported in a new study.

Molecular Targeting Technologies, a privately owned biotech company, recently won a patent for its 18F-fluroglucaric acid necrosis agent.

SNMMI said V/Q scans can be increasingly incorporated as a normal part of the workup of suspected pulmonary embolism.